These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21931032)

  • 1. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.
    Vergote I; Tropé CG; Amant F; Ehlen T; Reed NS; Casado A
    J Clin Oncol; 2011 Nov; 29(31):4076-8. PubMed ID: 21931032
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy is rarely the easy way out.
    Robinson WR
    J Clin Oncol; 2012 May; 30(13):1563; author reply 1563-4. PubMed ID: 22412132
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the easier way ever the better way?
    Chi DS; Bristow RE; Armstrong DK; Karlan BY
    J Clin Oncol; 2011 Nov; 29(31):4073-5. PubMed ID: 21931018
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
    van Meurs HS; Tajik P; Hof MH; Vergote I; Kenter GG; Mol BW; Buist MR; Bossuyt PM
    Eur J Cancer; 2013 Oct; 49(15):3191-201. PubMed ID: 23850170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant chemotherapy in the treatment of ovarian cancer].
    Lehoczky O
    Orv Hetil; 2005 Sep; 146(38):1951-5. PubMed ID: 16238247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology.
    Cornelis S; Van Calster B; Amant F; Leunen K; van der Zee AG; Vergote I
    Int J Gynecol Cancer; 2012 Mar; 22(3):407-16. PubMed ID: 22367320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
    Yan X; An N; Jiang GQ; Gao M; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
    J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions.
    Onda T; Yoshikawa H
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1053-67. PubMed ID: 21806329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LTE-commenting on "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer" (90: 163-9).
    Eisenkop SM
    Gynecol Oncol; 2004 Mar; 92(3):1017-8; author reply 1018-9. PubMed ID: 14984983
    [No Abstract]   [Full Text] [Related]  

  • 12. Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer.
    Ikeba K; Okubo M; Takeda S; Kinoshita K; Maeda H
    Int J Clin Oncol; 2004 Apr; 9(2):113-9. PubMed ID: 15108043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study.
    Machida H; Matsuo K; Enomoto T; Mikami M
    J Gynecol Oncol; 2019 Nov; 30(6):e113. PubMed ID: 31576698
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients.
    Cascales-Campos P; Gil J; Gil E; Feliciangeli E; López V; Gonzalez AG; Ruiz-Pardo J; Nieto A; Parrilla P
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():88-93. PubMed ID: 24965986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for advanced ovarian cancer.
    Schwartz PE; Chambers JT; Makuch R
    Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
    Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.